Wall Street brokerages expect that Repligen Corporation (NASDAQ:RGEN) will report earnings per share of $0.11 for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Repligen Corporation’s earnings. The highest EPS estimate is $0.15 and the lowest is $0.09. Repligen Corporation posted earnings per share of $0.08 in the same quarter last year, which would indicate a positive year-over-year growth rate of 37.5%. The company is scheduled to report its next earnings report on Thursday, November 2nd.
On average, analysts expect that Repligen Corporation will report full year earnings of $0.59 per share for the current year, with EPS estimates ranging from $0.57 to $0.61. For the next financial year, analysts anticipate that the business will report earnings of $0.74 per share, with EPS estimates ranging from $0.72 to $0.78. Zacks’ EPS averages are an average based on a survey of sell-side research firms that cover Repligen Corporation.
Repligen Corporation (NASDAQ:RGEN) last posted its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.15 by $0.05. Repligen Corporation had a net margin of 15.61% and a return on equity of 9.90%. The firm had revenue of $32.40 million for the quarter, compared to the consensus estimate of $31.72 million. During the same quarter in the prior year, the company posted $0.16 earnings per share. The company’s revenue for the quarter was up 11.0% compared to the same quarter last year.
Several equities research analysts recently weighed in on the company. BidaskClub upgraded Repligen Corporation from a “hold” rating to a “buy” rating in a research note on Wednesday, August 9th. Zacks Investment Research upgraded Repligen Corporation from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research note on Saturday, August 12th. Jefferies Group LLC restated a “hold” rating and set a $40.00 target price on shares of Repligen Corporation in a research note on Thursday, October 19th. TheStreet upgraded Repligen Corporation from a “c+” rating to a “b-” rating in a research note on Friday, August 11th. Finally, Stephens restated an “overweight” rating and set a $50.00 target price on shares of Repligen Corporation in a research note on Tuesday, September 26th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $45.40.
A number of hedge funds and other institutional investors have recently modified their holdings of RGEN. BlackRock Inc. lifted its stake in Repligen Corporation by 143,196.5% in the first quarter. BlackRock Inc. now owns 4,664,302 shares of the biotechnology company’s stock valued at $164,187,000 after buying an additional 4,661,047 shares during the last quarter. Lord Abbett & CO. LLC lifted its stake in Repligen Corporation by 330.9% in the second quarter. Lord Abbett & CO. LLC now owns 851,360 shares of the biotechnology company’s stock valued at $35,280,000 after buying an additional 653,791 shares during the last quarter. TimesSquare Capital Management LLC lifted its stake in Repligen Corporation by 19.8% in the second quarter. TimesSquare Capital Management LLC now owns 2,361,270 shares of the biotechnology company’s stock valued at $97,851,000 after buying an additional 390,545 shares during the last quarter. William Blair Investment Management LLC lifted its stake in Repligen Corporation by 49.8% in the second quarter. William Blair Investment Management LLC now owns 1,058,976 shares of the biotechnology company’s stock valued at $43,884,000 after buying an additional 352,045 shares during the last quarter. Finally, PointState Capital LP purchased a new stake in Repligen Corporation in the second quarter valued at approximately $11,984,000. Institutional investors own 96.45% of the company’s stock.
Repligen Corporation (NASDAQ:RGEN) opened at 37.62 on Friday. Repligen Corporation has a 12-month low of $26.16 and a 12-month high of $46.81. The firm has a market cap of $1.41 billion, a P/E ratio of 73.62 and a beta of 1.18. The stock’s 50 day moving average is $40.03 and its 200 day moving average is $39.88.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/11/11/repligen-corporation-rgen-expected-to-post-earnings-of-0-11-per-share-2.html.
Repligen Corporation Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Get a free copy of the Zacks research report on Repligen Corporation (RGEN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.